Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma

Published:2015-12-14 Issue:3 Volume:77 Page:477-484
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Belli Carmen,Piemonti Lorenzo,D’Incalci Maurizio,Zucchetti Massimo,Porcu Luca,Cappio Stefano,Doglioni Claudio,Allavena Paola,Ceraulo Domenica,Maggiora Paola,Dugnani Erica,Cangi Maria Giulia,Garassini Greta,Reni Michele

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2932-3.pdf

Reference40 articles.

1. Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomized controlled multicenter phase III trial. Lancet Oncol 6:369–376

2. Conroy T, Desseigne F, Ychou M et al: Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

3. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J 69:1691–1703

4. Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648

5. Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress on the role of tumor‑associated macrophages in tumor development and their use as molecular targets (Review);International Journal of Oncology;2023-12-07

2. Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers;Frontiers in Endocrinology;2023-04-27

3. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review;Cancer Treatment Reviews;2023-02

4. Marine-Inspired Drugs and Biomaterials in the Perspective of Pancreatic Cancer Therapies;Marine Drugs;2022-11-01

5. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples;Clinical Gastroenterology and Hepatology;2022-10